A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival

Table 3 Place of treatment of the 412 DLBCL patients with data on RDI included in the AMARE cohort study and comparisons between RDI groups

		Total		RDI < 85% (n = 72)		RDI ≥ 85% (n = 340)		P value^a
		n	%	n	%	n	%	P value^a
Place of treatment	Private centres	104	25.2	22	30.6	82	24.1	0.002
	TUMC	180	43.7	18	25	162	47.7
	Community hospitals	128	31.1	32	44.4	96	28.2

In bivariate analyses, p-values derived from the chi2 test ^a.
DLBCL: diffuse large B-cell lymphoma; RDI: relative dose intensity; TUMC: Toulouse university medical centre.

ISSN: 1471-2407